Product: Bausch + Lomb has announced the U.S. commercial launch of Miebo (perfluorohexyloctane ophthalmic solution) for the treatment of the signs and symptoms of dry eye disease. 
Top Line: Miebo is the first and only prescription eye drop approved for dry eye disease that directly targets tear evaporation.
Close Up: Miebo is a single ingredient, water-, preservative- and steroid-free prescription eye drop that spreads quickly and comfortably. It is designed to address the signs and symptoms of dry eye disease by reducing tear evaporation at the ocular surface.
Vital Statistics: The U.S. Food and Drug Administration (FDA) approved Miebo in May 2023, based on consistent results from two pivotal phase 3 trials. In the clinical trials, Miebo delivered significant improvements in the signs and symptoms of dry eye disease and consistently met its primary clinical sign and patient-reported symptom endpoint.
https://www.bausch.com/